Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 188

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 188
---
, and will be granted in the employee income
track or the capital gains track.

Options granted under the
2024 Plan are subject to applicable vesting schedules and generally expire 10 years from the grant date. In the event that options allocated
under the 2024 Plan expire or otherwise terminate in accordance with the provisions of the 2024 Plan, such expired or terminated options
will become available for future grant awards and allocations under the 2024 Plan.

<div align='center'>113

PRINCIPAL SHAREHOLDERS</div>

The following table sets
forth information with respect to the beneficial ownership of our Ordinary Shares as of October 24, 2025 by:

| ● | each person or entity known                                              
 by us to own beneficially 5% or more of our outstanding Ordinary Shares; |

| ● | each of our directors and            
 executive officers individually; and |

| ● | all of our directors and       
 executive officers as a group. |

The beneficial ownership
of our Ordinary Shares is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises
sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below,
we deem Ordinary Shares issuable pursuant to options or warrants that are currently exercisable or exercisable within 60 days of the
date of this registration statement to be outstanding and to be beneficially owned by the person holding the options for the purposes
of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage
ownership of any other person. Percentage of shares beneficially owned before this offering is based on 3,929,378 Ordinary Shares issued
and outstanding as of October 24, 2025. The number of Ordinary Shares deemed issued and outstanding after this offering is based on 1,000,000
Ordinary Shares offered hereby but assumes no exercise of the Representative’s over-allotment option.

As of October 24, 2025,
and based on their reported registered office, none of our shareholders were U.S. persons. We have also set forth below information known
to us regarding any significant change in the percentage ownership of our Ordinary Shares by any major shareholders during the past three
years. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners
of the Ordinary Shares listed below have sole investment and voting power with respect to such shares